Last updated: March 2026
Propranolol (Inderal) is a non-selective beta-adrenergic receptor antagonist FDA-approved since 1967. It blocks the physical effects of adrenaline — eliminating the racing heart, tremor, and voice shakiness of performance anxiety — without sedation. Also under active investigation for PTSD memory reconsolidation blockade and has established uses in migraine prophylaxis and essential tremor.
Propranolol is a competitive antagonist at both beta-1 (cardiac) and beta-2 (bronchial, vascular) adrenergic receptors — this non-selectivity underlies both its broad applications and its key contraindications.
Propranolol competitively blocks epinephrine and norepinephrine from activating beta-adrenergic receptors. Beta-1 blockade reduces heart rate and cardiac contractility — lowering blood pressure and preventing tachycardia. Beta-2 blockade in peripheral vasculature and airways is why propranolol is contraindicated in asthma and COPD: it can cause bronchoconstriction and mask hypoglycemia symptoms in diabetics.
Propranolol eliminates the somatic (physical) symptoms of anxiety — palpitations, tremor, sweating, voice shakiness — without touching the cognitive or emotional experience. This is why performers, surgeons, athletes, and public speakers use it: you remain fully cognitively engaged and emotionally present, but your body doesn't telegraph fear to your audience. It's fundamentally different from benzodiazepines, which sedate and impair performance.
When a consolidated memory is retrieved, it briefly re-enters a labile state (reconsolidation window) where it can be modified. Noradrenergic signaling is critical for reconsolidation of emotionally arousing memories. If propranolol is administered before or shortly after traumatic memory retrieval, beta-adrenergic blockade may impair reconsolidation — reducing the emotional salience of the memory without erasing the factual content. Multiple Phase 2 trials show reduction in PTSD symptom scores and physiological reactivity.
For migraine prophylaxis, propranolol reduces frequency and severity by approximately 50% in responders — mechanism involves reducing cerebrovascular reactivity and possibly central serotonergic effects. For essential tremor, propranolol reduces tremor amplitude by ~50-60% through peripheral beta-2 blockade in muscle spindle loops. These are among the best-established indications with decades of RCT evidence.
Propranolol's multi-decade evidence base spans many indications with varying levels of evidence.
Monitoring tools for blood pressure and heart rate management.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Propranolol is a prescription medication. It has serious contraindications including asthma, COPD, certain cardiac conditions, and diabetes. Do not use propranolol without medical supervision. Do not stop propranolol abruptly if taking it daily. Always consult a qualified physician before starting beta blocker therapy.